WATCH LIVE
timothy sykes logo
CANF Stock Jumps As Japan Patent Fuels Obesity Drug Hopes Thumbnail
G Google News

CANF Stock Jumps As Japan Patent Fuels Obesity Drug Hopes

TIM SYKES•UPDATED JUL. 1, 2026, 9:18 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Can-Fite Biopharma Ltd stocks have been trading up by 62.63 percent following highly positive drug development news.

Key Takeaways

  • Can-Fite BioPharma received an allowance from the Japan Patent Office for a patent covering A3 adenosine receptor agonists, including lead candidate Namodenoson, for fat loss, obesity and related metabolic disorders.
  • The new Japanese patent adds to existing intellectual property protection for Namodenoson and related compounds in the U.S., Canada, Australia, Israel and other major regions for anti-obesity use.
  • Following the patent news, Can-Fite BioPharma’s stock is up about 18% in premarket trading, signaling strong early interest from active biotech traders.

Candlestick Chart

Live Update At 09:18:03 EDT: On Wednesday, July 01, 2026 Can-Fite Biopharma Ltd stock [NYSE American: CANF] is trending up by 62.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CANF is a classic small-cap biotech story: tiny revenue, heavy R&D focus, and big swings when real news hits. Can-Fite Biopharma Ltd reported only about $0.67M in revenue, and its revenue trend over the past three and five years has gone sharply negative. That lines up with a development-stage biotech where the pipeline, not current sales, drives the narrative.

The balance sheet shows roughly $9.12M in total assets and about $5.44M in equity as of 2024/12/31, with cash around $4.83M and working capital near $6.93M. For CANF traders, that cash pile matters more than earnings. It tells you how long the company can keep pushing Namodenoson and the rest of its A3 adenosine receptor program without tapping markets again.

More Breaking News

On the flip side, valuation ratios scream “speculative.” A price-to-sales north of 19,700 and price-to-book over 1,400 show traders are paying almost entirely for future potential. Return on assets and return on equity are both negative, reflecting ongoing losses. For CANF, every major catalyst — like this Japan patent — can sharply reset sentiment because the fundamentals alone do not justify the market cap.

Why Traders Are Watching CANF’s Patent Momentum

CANF exploded in premarket trading after Can-Fite Biopharma Ltd announced a fresh win from the Japan Patent Office. The allowance covers Namodenoson and other A3 adenosine receptor agonists for fat loss, obesity and metabolic disorders. In one move, CANF added a key Asian market to its obesity playbook and sparked an 18% early surge.

For active traders, this is exactly the kind of news CANF is built for. The stock had been grinding around the high-$2s and low-$3s for weeks. Daily closes between roughly $2.82 and $3.06 showed a tight range with no clear trend. Then the patent headline hit, and the premarket tape flipped from sleepy to wild.

The intraday 5‑minute chart tells the story. CANF jumped from the prior close near $2.75–$2.97 straight into the $5–$6 zone at 07:00–07:10, touching an intraday high near $6.79 before fading. That’s more than a 100% spike at the top, followed by fast profit‑taking — textbook biotech momentum.

Beyond the chart, the strategic angle matters. CANF already had anti‑obesity intellectual property for Namodenoson in the U.S., Canada, Australia, Israel and other regions. Japan now plugs a major gap in Asia. For traders, that expanded IP estate suggests Can-Fite Biopharma Ltd is serious about carving out long-term optionality in the crowded obesity space, rather than just chasing a single local market.

Still, this is all about potential, not guaranteed cash flows. The market is showing that it values CANF’s growing patent wall, but it will keep repricing the stock with every clinical update and financing rumor. That’s why disciplined trade planning around these spikes is crucial.

Conclusion

CANF now sits at the center of two powerful forces: a hot global obesity drug theme and a tiny balance sheet that depends on catalysts. The new Japanese patent for Namodenoson and other A3 adenosine receptor agonists clearly matters. It stretches Can-Fite Biopharma Ltd’s anti‑obesity IP across North America, Australia, Israel, and now Japan, giving the company a broader platform if future trial data cooperate.

For traders, the tape action says just as much as the news itself. CANF ran hard on the headline, with premarket levels blasting into the mid‑$5s and beyond before volatility kicked in. Anyone chasing without a plan felt that snapback. That’s the pattern you should expect in a thin, development-stage biotech like Can-Fite Biopharma Ltd — sharp moves, big gaps, and no safety net from steady earnings.

The key going forward is to track how CANF trades around support levels built after this spike and watch for follow‑through news on Namodenoson’s clinical progress. The Japanese patent win is real, but the market will quickly ask, “What’s next?” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” That mindset matters here because managing risk and protecting trading capital is just as critical as spotting the next headline catalyst.

As Tim Sykes likes to remind traders, “The news is only half the story — the chart tells you how to trade it.” CANF’s latest move is a live lesson in that idea. Use the patent headlines as a catalyst, study the price action, and always cut losses fast. This coverage is for educational and research purposes only, and every trader must make their own decisions.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”